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quantified via microarray gene chips. We observed a negative association of CXCL5 levels with CAD at an
odds ratio (OR) of 0.46 (95% CI, 0.27e0.75). Controlling for covariates, including sex, statin use,
hypertension, hyperlipidemia, obesity, self-reported race, smoking, and diabetes, the OR was not
significantly affected [OR, 0.54 (95% CI, 0.31e0.96)], consistent with a protective role for CXCL5 in
coronary atherosclerosis. We also identified 18 genomic regions with expression quantitative trait loci
of genes correlated with both CAD severity and circulating CXCL5 levels. Our clinical findings are
consistent with the emerging link between chemokines and atherosclerosis and suggest new therapeutic
targets for CAD. (Am J Pathol 2017, 187: 2895e2911; https://doi.org/10.1016/j.ajpath.2017.08.006)Supported by a Le Fondation Leducq Trans-Atlantic Network of
Excellence grant, The University of North Carolina at Chapel Hill grant
6066230 (Investments in the Future: Understanding Clinical Cardiovascular
Disease and Health Disparities in North Carolina Using a Systems Biology
Approach), American Heart Association grant 16GRNT29300003 (C.R.L.)
and predoctoral fellowship 11PRE7240059 (R.N.S.), NIH/National Heart,
Lung, and Blood Institute (NHLBI) predoctoral training program in Inte-
grative Vascular Biology T32 HL069768, and NIH/NHLBI grant
4R37HL065619 (C.P.). The Genotype-Tissue Expression Project was
supported by the Common Fund of the Office of the Director of the NIH
and by National Cancer Institute, National Human Genome Research
Institute, NHLBI, National Institute of Drug Abuse, National Institute of
Mental Health, and National Institute of Neurological Diseases and Stroke.
Disclosures: None declared.It is well established that age is associated with cardiovas-
cular disease (CVD) risk. Epidemiological studies demon-
strated that the lifetime risk for CVD remains high in older
individuals and increases dramatically in the presence of
multiple risk factors.1 In addition, older individuals who
experience an acute coronary syndrome have a poorer
prognosis compared with the general population. For
example, in patients aged 65 years or older, the 5-year
mortality rate after a myocardial infarction is 46% to 58%,
and all-cause mortality, death from cardiovascular causes,
recurrent myocardial infarction, and stroke are all higher
compared with younger individuals.2 However, older
patients are frequently underrepresented in clinical trials,
and the pathophysiology underlying the development and
progression of atherosclerotic coronary artery disease
(CAD) has not been rigorously evaluated in this population.
Increasing age is associated with pathophysiological
changes in the vasculature, including increased carotidintima-media thickness, arterial stiffening, endothelial
dysfunction, and elevated systolic blood pressure.3 Although
it is well established that systemic and vascular inflammation
are important in the development and progression of CAD in
the general population,4e6 differing reports on inflammatory
markers and their association with CAD are found throughout
the literature. It remains unclear how age modifies the disease
process. Although studies have looked at the use of statins
and treatment of hypertension in geriatric cohorts,7,8 further
analyses are needed to ascertain the inflammatory processes
that are involved in the pathophysiology of CVD in older
adults. More important, identification of the key biological
processes underlying CAD in the older high-risk geriatric
patient population may facilitate the development of novel
therapeutic strategies to improve prognosis.
Systems biology studies identified global gene expression
signatures in peripheral blood mononuclear cells (PBMCs)
that are predictive of the presence and extent of CAD.9,10 In
addition, changes in gene expression in peripheral blood
mirror changes in gene expression in atherosclerotic arteries.9
Therefore, evaluation of global gene expression changes in
PBMCs represents a nonbiased approach to elucidating the
key mechanisms underlying CAD. Likewise, genomic data
and quantification of circulating factors that are thought to
contribute to inflammation can be combined with gene
expression data to identify molecular phenotypes and eluci-
date the potential dysregulation of biological pathways that
are associated with the presence and severity of obstructive
CAD, potentially uncovering new therapeutic targets.
The ELRþ-CXCL chemokines contain a glutamic acid-
leucine-arginine motif (ELR) and are classically defined as
chemoattractants and are involved in neutrophil activation in
models of acute inflammation. In chronic inflammatory
disease, such as atherosclerosis, ELRþ-CXC chemokines
are proposed to be involved throughout the pathophysio-
logical response. Of particular interest to our study was the
leukocyte-derived CXCL5 (initially described as epithelial
neutrophil-activating peptide-78), because of the observed
increases in CXCL5 with subclinical atherosclerosis in type
2 diabetics and CAD (as defined as 70% narrowing of one
epicardial coronary artery) in Chinese populations.11,12
These results seem to be at odds with the protective role
for CXCL5 in a mouse model of atherosclerosis.13 There-
fore, we investigated the relationship between circulating
CXCL5 and CAD in a clinical cohort from the southeastern
United States and used a systems biology approach to un-
derstand the genetic influences of CXCL5 regulation and
molecular phenotypes associated with CAD.
Materials and Methods
Study Population
Phase 2 of the Supporting a Multidisciplinary Approach to
Researching Atherosclerosis (SAMARA) study enrolled
individuals who were at least 65 years old and undergoing
clinically indicated diagnostic cardiac catheterization.
Between March 2007 and February 2009, 200 individuals
from The University of North Carolina Cardiac Catheteriza-
tion Laboratory were enrolled. Individuals with a history of
any of the following conditions were not eligible to participatein this study: HIV or hepatitis C virus infection, lymphoma,
leukemia, anemia, rheumatoid arthritis, lupus, solid organ
transplantation, active cancer treatment, or chronic immuno-
suppressive therapy. Participants were interviewed to obtain
pertinent medical information, including medical history,
current medication use, family medical history, and tobacco
use. This study was approved by The University of North
Carolina Institutional Review Board (number 05-1798) and
conducted according to institutional guidelines; all partici-
pants provided written informed consent.
CAD Severity
Subjects underwent clinically indicated diagnostic left heart
catheterization with coronary angiography. After the pro-
cedure, angiograms were reviewed independently by two
cardiologists and CAD severity was quantified in each subject
on either an ordinal scale (range, 0 to 4) or binary classifi-
cation (obstructive CAD, yes/no). The ordinal CAD score
was calculated as follows: 0 (<10% stenosis in all major
coronary arteries), 1 (10% to 70% stenosis in one vessel, left
main coronary artery excluded), 2 (>70% stenosis in one
vessel), 3 (>70% stenosis in two vessels), and 4 (>70%
stenosis in 3 vessels or >50% stenosis in the left main cor-
onary artery). Obstructive CAD was defined as >70% ste-
nosis in one or more major epicardial coronary arteries or
>50% left main coronary artery stenosis. Subjects with
70% occlusion in any vessel or <50% in the left main
coronary artery were considered free of obstructive CAD.14,15
Sample Collection and Processing
All catheterizations took place in the morning after an
overnight fast. A complete blood cell count (without dif-
ferential) was performed as routine care on the day of the
catheterization. Lipid panel data were obtained from a
previous office visit (within 6 months before catheteriza-
tion). At the start of the procedure, 30 mL of blood was
drawn from the femoral artery into Na-EDTA Vacutainer
tubes (Becton, Dickinson and Co, Cockeysville, MD).
After blood collection, RNA and DNA were isolated from
PBMCs, as described.16,17 RNA quantity, purity, and
integrity were assessed by spectrophotometry and micro-
capillary electrophoresis on an Agilent BioAnalyzer 2100
(Agilent Technologies, Inc., Santa Clara, CA). Only RNA
with an A260/280 ratio of 1.8 and an electrophoretic
profile consistent with only minimal degradation was
considered acceptable for use. An additional 8 mL of
blood collected in tubes containing EDTA and proteinase
inhibitor was processed to plasma, aliquoted, and stored
at 80C, pending analysis.
Quantification of Circulating Markers of Inflammation
Plasma samples from 143 of the 200 subjects were used to
measure circulating inflammatory mediators. We limited
these analyses (n Z 143) to only self-reported blacks and 
whites and avoided potential inflammatory bias by 
excluding subjects who were diagnosed as having acute 
infections. Plasma concentrations of cellular adhesion 
molecules (CAMs; E-selectin, P-selectin, intracellular 
adhesion molecule-1, and vascular CAM-1) and chemokines 
[monocyte chemoattractant protein (MCP)-1 and CXCL5] 
were quantified using the Human Adhesion Molecule and 
Human Cytokine Fluorokine Multi-Analyte Profiling Kits 
(R&D Systems, Minneapolis, MN), respectively.18 High-
sensitivity C-reactive protein (hsCRP) was quantified using 
the Human C-Reactive Protein Fluorokine MAP Kit for Use 
in Cardiac Panel B (R&D Systems, Minneapolis, MN). All 
analytes were quantified with fluorescence detection on the 
Bio-Plex 200 System (Bio-Rad, Hercules, CA), according to 
the manufacturer’s instructions, at the Bioanalytical Core 
Laboratory at The University of North Carolina at Chapel 
Hill. Because hsCRP was higher than the limit of detection 
in 53 (37%) of the samples analyzed, a value of 15.2 mg/L 
(1.5-fold higher than the highest standard) was imputed for 
each sample above the upper limit of detection; in addition, 
we stratified subjects by hsCRP level higher or lower than 
the median. Pearson and Spearman correlation analyses were 
used to determine the correlation among circulating bio-
markers of inflammation. Multiple CAMs were correlated at 
P < 0.05 and correlation coefficients at >0.2 (Supplemental 
Table S1). To minimize redundancy in our analysis, a 
consolidated CAM score phenotype was calculated for each 
individual by summing the z-scores of E-selectin, P-selectin, 
intracellular adhesion molecule-1, and vascular CAM-1.18,19 
The association between plasma levels of the selected 
inflammatory biomarkers and obstructive CAD status or 
ordinal CAD score was evaluated using nominal or ordinal 
logistic regression, respectively, using an unadjusted model 
and a model that adjusted for the indicated variables (JMP 
Pro 12; SAS, Cary, NC).
Gene Chip Analysis
RNA labeling, hybridization, and data extraction were per-
formed in our laboratory. RNA was cohybridized to Agilent 
G4112F Whole Human Genome 4  44K oligonucleotide 
arrays (Agilent Technologies, Inc.) in the presence of 
cyanine-3elabeled Universal Human Reference RNA 
(Stratagene, La Jolla, CA) for array normalization, as 
described.16 Slides were hybridized and washed, then 
scanned on an Axon 4000b microarray scanner; data were 
processed using Feature Extraction version 9.5.1.1 (Agilent 
Technologies, Inc.). Probes were filtered by only including 
probes flagged as detected in at least 85% of all SAMARA 
phase 2 samples, resulting in 18,411 probes available for 
analysis. In addition, samples were filtered by only 
including RNA samples with at least 90% of the 18,411 
probes flagged as detected. Missing data were imputed 
using the k-nearest neighbor algorithm (k Z 10). Data sets 
were deposited in the Gene Expression Omnibus (GEO) ofthe National Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/geo; accession number GSE90074)
containing the 143 samples used in the biomarker
analyses. The processing date (batch effect) and sex were
controlled for using an analysis of variance linear model
using Partek Genomics Suite version 6.6 (Partek Inc.,
Chesterfield, MO). Probes were updated using the
annotations updated by Agilent on June 12, 2015. We
used BioMart version 0.9 identification conversion (http://
www.biomart.org)20 for all significant probes that
contained missing associated gene name annotations.
Spearman rank correlation was used to generate a list of
genes that correlated with the CAD score (range, 0 to 4)
with a predefined cutoff of jrsj  0.25 using Partek
Genomics Suite v6.6, as described.9 SAMARA phase 1
microarray data were downloaded from GEO (accession
number GSE12959), as previously described.17
DNA labeling, hybridization, and data extraction were
performed by the DNA Array Core Facility at The Scripps
Research Institute (Jupiter, FL). The Genome-Wide Human
SNP Array 6.0 (Affymetrix, Santa Clara, CA) was used for
hybridizations. We obtained high-purity DNA samples from
126 of the 143 subjects with gene expression and biomarker
analyses that were analyzed via single-nucleotide poly-
morphism (SNP) array. Subsequently, 20 of the 126 arrays
had no call rates of >20% and were dropped from further
analysis, leaving 106 samples with 909,624 probes. Data
sets were deposited in the GEO of the National Center for
Biotechnology Information (GEO series accession number
GSE90073). SNP probes were filtered to include only those
with minor allele frequencies >0.05 and Hardy-Weinberg
equilibrium >0.01, leaving 398,997 available for analysis.
Principal components analysis was used to classify subjects
as Americans with either African or European ancestry.
Missing genotypes were imputed using MaCH version 1.0.6
(http://csg.sph.umich.edu/abecasis/mach/index.html)21 with
estimated mismatch rates in the Markov model of 0.1256
and 0.00481 in each group, respectively.
eQTL Analysis
Identification of local elements associated with expression
[expression quantitative trait loci (eQTL)] was performed
with Matrix eQTL version 2.1.022 in the software package R
version 3.2.1 (https://www.r-project.org).23 We used the
linear additive model to identify cis-acting eQTLs (distance
between SNP and expression probe, <1e6 bp) accounting
for ancestry covariance and population structure. This
resulted in testing 4,600,673 SNP-gene pairs in the 106
subjects with both DNA and RNA analyses. The DNA and
RNA data sets are collated as a SuperSeries in the GEO of
the National Center for Biotechnology Information (GEO
series accession number GSE90076). Where indicated,
additional data used for the analyses described herein were
obtained from the GTEx Portal (https://www.ncbi.nlm.nih.
gov/gap, accession number phs000424.v6.p1).
Table 1 Study Population Characteristics by Obstructive CAD Status
Characteristic Obstructive CAD (n Z 93) No obstructive CAD (n Z 50) P value
Age, years 74  6.3 73  6.2 0.220
Male sex* 57 (61) 18 (36) 0.004
White race 74 (80) 37 (74) 0.446
Body mass index, kg/m2 29  6.3 30  7.1 0.323
Current smoker 4 (4) 3 (6) 0.653
Diabetes 38 (41) 17 (34) 0.421
Hyperlipidemia* 74 (80) 28 (56) 0.003
Hypertension 82 (88) 44 (88) 0.976
Previous MI* 41 (44) 3 (6) <0.001
Multivessel disease* 62 (67) 0 (0) <0.001
Systolic blood pressure, mmHg 143  20 141  20 0.573
Diastolic blood pressure, mmHg 77  13 78  12 0.588
Statin use* 74 (80) 23 (46) <0.001
Aspirin use* 78 (84) 33 (66) 0.015
Clopidogrel use* 33 (36) 6 (12) 0.003
Data presented as means  SD or n (%). Age, body mass index, and diastolic blood pressure were not normally distributed and were log transformed before
analysis.
*P < 0.05 (t-test).
CAD, coronary artery disease; MI, myocardial infarction.Overlap of Two Groups of Genes
The probability of overlap of two groups of genes was deter-
mined by measuring the hypergeometric distribution using the
number of probes that passed quality control measures
(18,411). To compare the gene expression signatures identified
in our analysis with those previously identified in CAD pa-
tients, we accessed the published list of 655 genes24 that were
associatedwithCAD in the case-control analyses fromboth the
CATHeterization GENetics (CATHGEN)10 and Personalized
Risk Evaluation andDiagnosis in the Coronary Tree cohorts.25
Results
Study Population
The study population characteristics of the 143 subjects strat-
ified by obstructiveCADstatus are shown inTable 1.A total of
93 subjects (65%) had obstructive CAD, whereas 50 subjects
(35%) did not have obstructive CAD. In both groups, most
subjects were white and had multiple comorbidities, including
hyperlipidemia and hypertension. More of those diagnosed as
havingobstructiveCADweremen, had a previous diagnosis of
hyperlipidemia or myocardial infarction (MI), and were taking
medications for the treatment of CVD, including statins,
aspirin, and clopidogrel. There was no difference in lipid
profiles, white blood cell count, or platelet count between the
two groups at P < 0.05 (Supplemental Table S1).
Circulating Biomarkers of Inflammation
The Protective Chemokine CXCL5 Inversely Correlates with
CAD Severity
Given the proposed protective role for CXCL5 in athero-
sclerosis, we hypothesized that CXCL5 levels would varyinversely with disease severity in our cohort. To test our
hypothesis, we measured levels of CXCL5 in plasma and
used logistic regression to measure the association be-
tween CAD severity and circulating levels of CXCL5. We
observed a negative association between CXCL5 levels
and CAD severity using either ordinal (Figure 1A) or
nominal (Figure 1B) classification, with odds ratios (ORs)
of 0.52 and 0.46, respectively (Table 2 and Figure 1). To
control for other potential confounding variables, we
included sex, prior statin use, hyperlipidemia, self-reported
race, obesity, hypertension, smoking, and diabetes in an
adjusted model. When we controlled for these variables,
the ORs for CXCL5 and CAD severity were similar to the
unadjusted model, 0.59 and 0.54, in both the ordinal and
nominal models, respectively, and within the 95% CI of
the unadjusted ORs (Table 2). Of the variables included in
the model, only prior statin use, sex, and CXCL5 associ-
ated with CAD classification (P < 0.05); the other vari-
ables had no association with CAD score (Supplemental
Table S2).26 In addition, the fit of both ordinal and lo-
gistic models with the above risk factors was improved
when circulating CXCL5 levels were included in the
model (Supplemental Table S2).
Both sex and prior statin use covariates were of particular
interest to the CAD-CXCL5 association. First, studies in
younger populations identified higher circulating levels of
CXCL5 in women compared with men,27 and our geriatric
cohort reflected a similar observation (1.8  1.7 and
1.3  0.9 ng/mL in women and men, respectively, repre-
sented by the means  SD; P Z 0.019). To explore the
possible confounding of sex on the CXCL5-CAD associa-
tion (Table 1), we measured the association of CXCL5
levels and the interaction between sex and obstructive CAD
class using a two-way analysis of variance. Only CAD
status had a significant association with CXCL5
Table 2 Regression Analysis of Plasma CXCL5 Levels and CAD Score
Analyte P value OR (95% CI) Reciprocal OR CAD Class 0e4
Ordinal
CXCL5 unit odds 0.0013 0.52 (0.36e0.78) 1.91 1570, 1638, 1048, 1324, 886
Adjusted model
CXCL5 unit odds adj 0.0148 0.59 (0.39e0.90) 1.69
Prior statin use (Y) adj 0.0023 1.75 (1.15e2.67) 5%, 19%, 25%, 21%, 31%
Sex (M) adj 0.0003 1.78 (1.27e2.48) 7%, 17%, 18%, 24%, 33%
Analyte P OR (95% CI) Recip Obstructive CAD-no Obstructive CAD-yes
Nominal
CXCL5 unit odds 0.0014 0.46 (0.27e0.75) 2.15 1638 (1439) 998 (943)
CXCL5 range odds 0.03 (3.2E-3e0.30) 32.06
Adjusted model
CXCL5 unit odds adj 0.0309 0.54 (0.31e0.96) 1.84
CXCL5 range odds adj 0.06 (4.7E-3 - 0.84) 57.33
Prior statin usage (Y) adj 0.0100 4.02 (1.39e11.58) 46% 80%
Sex (M) adj 0.0140 3.03 (1.25e7.33) 36% 61%
We measured the associations between each CXCL5 and CAD score using nominal and ordinal logistic regression. The adj model controlled for sex, statin use,
hypertension, hyperlipidemia, obesity, self-reported race, smoking status, and diabetes. The P value of the effect likelihood test for each analyte in the model
at P < 0.05 and the OR (95% CI) are provided. The reciprocal OR is provided for ratios <1. Summary CXCL5 data are presented as median (interquartile range),
with units of pg/mL or percentage of subjects in the indicated category for statin use and sex.
M, male; Adj, adjusted model; CAD, coronary artery disease; OR, odds ratio; Y, yes.(P Z 0.007), whereas sex alone or the interaction between
sex and CAD status did not associate with CXCL5 levels
(P Z 0.139 and P Z 0.708, respectively). Furthermore, we
tested for a negative association between CAD and CXCL5
levels after stratifying the data set by sex and found that
CXCL5 levels decreased with obstructive CAD, irrespective
of sex (P Z 0.044 and P Z 0.018 in women and men,




















Figure 1 Plasma CXCL5 levels negatively associated with coronary ar-
tery disease (CAD) severity. Plasma levels of CXCL5 represented by dot plot 
and summarized by the means and 95% CIs of the log values. A: CXCL5 
levels in subjects with increasing CAD severity represented by dot plot, with 
the corresponding P value of the logistic regression analysis. B: CXCL5 
levels stratified by obstructive CAD status for the entire cohort (left of 
dashed line) or within each sex (right of dashed line). *P < 0.05 on CAD 
term testing the negative association between CAD and CXCL5 levels within 
each sex (t-test); yyP < 0.01 on CAD term from two-way analysis of variance 
of CXCL5, factoring sex and CAD. N, no; Y, yes.Statins decreased CXCL5 levels in an in vitro model of
inflammation using endothelial cells,28 suggesting that statin
use might confound our analysis of the CXCL5-CAD as-
sociation. Furthermore, CXCL5 is expressed in other cell
types, such as platelets, enterocytes, fibroblasts, microglia,
endometrial stromal cells, and various white blood
cells.29e36 Given the influence of statins on both CXCL5
and circulating lipids, as well as the various potential
sources of CXCL5 found in the blood, we performed pair-
wise association analyses of CXCL5 with lipid variables,
white blood cell count, and platelet count in our study
subjects. Interestingly, CXCL5 did not correlate with any of
the lipid molecules, but it did have a small positive corre-
lation with platelet count (Figure 2A). However, when
included in our adjusted model, platelet count did not
associate with CAD (P Z 0.74 and P Z 0.16 in the ordinal
and nominal models, respectively); inclusion of platelet
count did not affect the impact of CXCL5, statins, or sex on
CAD associations (data not shown). Similar to our two-way
analysis of variance analysis with sex and CAD status, we
observed an association between CXCL5 and CAD status
(P Z 0.005); however, there was no association between
CXCL5 levels and statin use (PZ 0.699) and no interaction
between statin use and CAD status with CXCL5 levels
(P Z 0.824). When we further stratified CXCL5 levels by
sex and obstructive CAD, we identified an association of
statin use and decreased CXCL5 only in women with
obstructive CAD (P Z 0.0098) (Figure 2B).
Statins vary in their low-density lipoproteinelowering
intensity and, hence, could differentially affect CXCL5
levels.37e39 To determine whether differences in statin
intensity correlated with CXCL5 levels, we examined the
Figure 2 Association of plasma CXCL5 levels
with lipids, cell counts, and statin use. A: Pairwise
association analysis of the indicated variables
summarized by the regression line and means
(95% CIs). The correlation coefficient for each
association is indicated and colored to reflect the
P value. BeD: CXCL5 levels represented by dot plot
and summarized by the means and 95% CIs of the
log values. B: CXCL5 levels stratified by obstructive
CAD status and statin use. C: CXCL5 levels strati-
fied by statin type; the P value from one-way
analysis of variance is indicated. D: CXCL5 levels
stratified by statin intensity; the P value from one-
way analysis of variance is indicated. **P < 0.01
for statin use with CXCL5 levels (t-test); yP < 0.05,
yyP < 0.01 versus rosuvastatin (Tukey post-test).
CAD, coronary artery disease; CHOL, cholesterol;
HDL, high-density lipoprotein; LDL, low-density
lipoprotein; N, no; PC, platelet counts; TG, tri-
glyceride; WBC, white blood cell; Y, yes.association of the five prescribed statins in our cohort to
circulating CXCL5 levels using analysis of variance.
Subjects prescribed the high-intensity statin rosuvastatin39
had lower levels of circulating CXCL5 compared with the
other statins. However, only three subjects were prescribed
rosuvastatin, and there were no other differences observed
across other statins when analyzed individually
(Figure 2C) or when grouped into high versus low in-
tensity (Figure 2D).
Given the age of our cohort (>65 years), it was not sur-
prising that 31% of the subjects had a previous MI; likewise,
a disproportionate number of subjects who were diagnosed as
having obstructive CAD in our study also had a previous MI
(Table 1). We found that CXCL5 levels were lower insubjects who had a previous MI (1.1  0.8 versus 1.7  1.5
ng/mL, represented by the means  SD in subjects with or
without a previous MI, respectively; P Z 0.025). Therefore,
we stratified our data set on subjects with or without a pre-
vious MI as well as CAD status to compare circulating
CXCL5 levels using analysis of variance. As with our
previous analyses (Figure 1), we observed that subjects with
CAD had lower levels of CXCL5, and that CXCL5 levels
were independent of a history of previous MI (Figure 3).
hsCRP, but Not Other Circulating Inflammatory Biomarkers,
Correlates with CAD Severity
Previous studies indicate that certain mediators of inflam-











Figure 3 Plasma CXCL5 levels negatively associated with coronary ar-
tery disease (CAD) severity, irrespective of a previous myocardial infarction 
(MI). Plasma levels of CXCL5 represented by dot plot and summarized by the 
means and 95% CIs of the log values in subjects stratified by previous MI 
and the presence of obstructive CAD; the P value from one-way analysis of 
variance is indicated. *P < 0.05, **P < 0.01 versus CAD [no (N)] and 
previous MI (N; Tukey post-test). Y, yes.CAMs, selectins, and MCP-1, associate with CAD 
incidence in the general population and predict higher 
mortality in patients with established CAD40e43; however, 
the association between these inflammatory biomarkers and 
disease severity, particularly in geriatric populations, is less 
clear. We measured these additional mediators and per-
formed the identical analyses, as we did for CXCL5. 
Surprisingly, only hsCRP associated with CAD classified 
either nominally (P Z 0.083) or on the ordinal scale 
(P Z 0.021) in the adjusted model at an OR of 1.1 
(Table 3). The association between CRP and severity of 
CAD is inconsistent and contradictory.44,45 Although 
hsCRP is a common marker of CVD risk, our results are 
similar to others that find hsCRP less effective at 
distinguishing CAD severity.46e49 Not surprisingly, hsCRP 
had small-to-moderate positive correlations with the CAM 
score and MCP-1, but no correlation with CXCL5 
(Supplemental Table S3). Likewise, the addition of hsCRP 
with CXCL5 to the adjusted model further increased the 
fitness of both the ordinal and nominal models of CAD, 
whereas addition of the CAM score and MCP-1 did not 
(Supplemental Table S2), suggesting that changes in hsCRP 
and CXCL5 reflect different pathophysiological processes.Global Gene Expression and Genotype Profiling
PBMCs are integral mediators of vascular inflammation and 
express signaling molecules that drive monocyte recruit-
ment and infiltration into the vessel, including cytokines, 
chemokines, and CAMs, ultimately leading to plaque 
development and obstructive CAD.50 The heritable 
component of gene expression variance is a combination of 
epigenetic and genetic factors, the latter of which we can 
measure by combining measures of DNA variation withCAD gene expression data to identify eQTL. We used gene
expression and genotype microarray data from the
SAMARA2 study to explore pathways and targets involved
in CXCL5-associated protection.
Polymorphisms Associated with CXCL5 Expression and
Circulating CXCL5 Levels
To identify genes and pathways that associate with circu-
lating CXCL5 and CAD severity, we first identified gene
expression changes that correlated with plasma CXCL5,
resulting in 1041 probes [absolute correlation coefficient
(rs)  0.25, corresponding to P  0.0026; false-discovery
rate, <7%], including the probe for CXCL5
(A_24_P277367). Previous studies identified poly-
morphisms at the CXCL5 locus that associate with changes
in PBMC CXCL5 mRNA and plasma CXCL5 levels,51,52
suggesting that genetic variance at the CXCL5 locus can
affect the expression and production of CXCL5 and that
these differences are detectable in PBMCs. Likewise, we
identified an eQTL for CXCL5 expression in our cohort
(rs394408jCXCL5) (Figure 4A). The expression regulatory
SNP (eSNP) rs394408 is not a rare variant in our population
(Supplemental Figure S1)54 and is in high linkage disequi-
librium (Supplemental Table S4) with these two other
known variants (rs425535 and rs352046) that correlated
with CXCL5 expression and plasma levels in both black and
white populations.55 To validate our findings on rs394408,
we analyzed the same eQTL in whole blood from 338 in-
dependent samples from the Genotype-Tissue Expression
project, consisting of 66% men and 84% whites (16%
blacks); their mean age was 53 years [The Database of
Genotypes and Phenotypes (dbGaP) phs000424.v6.p1].
This analysis confirmed our initial observation of the minor
allele of rs394408 associating with increased CXCL5
expression (Figure 4B).
In addition, we looked at eQTLs specifically in mono-
cytes at the locus containing rs394408 from 1490 Western
Europeans enrolled in the Gutenberg Heart Study, consist-
ing of 51% men (mean age, 55 years). Within this region on
chromosome 4, we identified a hotspot for CXCL5
cis-eQTLs (Figure 4C) in a region that also associated with
sex-based disease risk in immunity-based diseases and
atherosclerosis.53 We also confirmed this eQTL in the most
comprehensive circulating monocyte data set on >2000
Western Europeans from the Leipzig LIFE Heart Study
(Supplemental Table S5).56 Given that rs394408 is located
in a region containing two other chemokine genes, PF4
(CXCL4) and PPBP (CXCL7) (Figure 4C), we examined
the pairwise correlation between the expression levels of
these three chemokine genes and their association with
rs394408 to determine the relationship between the
expression of these genes and the potential influence of
DNA variation at rs394408. We observed a robust positive
correlation between PF4 and PPBP expression (Figure 4D)
compared with a much smaller correlation between CXCL5
and PF4 or PPBP expression. Furthermore, we did not
Table 3 Regression Analysis of Plasma Inflammatory Biomarker Levels and CAD Score
Analyte P value OR (95% CI) CAD Class 0e4
Ordinal
MCP1 0.706 0.90 (0.51e1.59) 106, 125, 132, 127, 109
MCP1 adj 0.586 0.99 (0.54e1.84)
hsCRP 0.105 1.04 (0.99e1.09) 4.9, 4.4, 4.3, 5.8, 8.1
hsCRP adj* 0.021 1.06 (1.01e1.12)
hsCRPmed [1] 0.137 1.55 (0.87e2.80) 11%, 20%, 18%, 21%, 30% [1]
hsCRPmed adj [1] 0.097 1.68 (1.59e1.76) 14%, 25%, 25%, 15%, 21% [0]
CAM score 0.285 1.08 (0.94e1.23) 0.12, 0.07, 0.044, 0.60, 0.16
CAM score adj 0.548 1.04 (0.91e1.20)
Analyte P OR (95% CI) Obstructive CAD-no Obstructive CAD-yes
Nominal
MCP1 unit 0.661 1.16 (0.59e2.29) 115 (46) 122 (58)
MCP1 range 1.77 (0.14e22.5)
MCP1 unit adj 0.521 1.30 (0.59e2.87)
MCP1 range adj 2.68 (0.13e54.5)
hsCRP unit 0.212 1.04 (0.98e1.10) 4.6 (13.8) 5.7 (13.1)
hsCRP range 1.72 (0.73e4.04)
hsCRP unit adj 0.083 1.06 (0.99e1.14)
hsCRP range adj 2.41 (0.88e6.63)
hsCRPmed [1] 0.321 1.42 (0.71e2.85) 15%/20% [1/0] 34%/31% [1/0]
hsCRPmed adj [1] 0.201 1.69 (0.75e3.80)
CAM score unit 0.485 1.06 (0.90e1.25) 0.07 (2.86) 0.10 (2.68)
CAM score range 1.92 (0.90e1.25)
CAM score unit adj 0.665 1.04 (0.87e1.25)
CAM score range adj 1.58 (0.20e12.6)
We measured the associations between each analyte and CAD score using nominal and ordinal logistic regression. The adj model controlled for sex, statin
use, hypertension, hyperlipidemia, obesity, self-reported race, smoking status, and diabetes. In addition, for hsCRP, the data were stratified higher than [1] or
lower than [0] hsCRPmed. The P value of the effect likelihood test for each analyte and the OR (95% CI) are provided. Summary data for continuous variables
are presented as the median value from each CAD class for ordinal classification of CAD or as the median (interquartile range) for nominal classification of CAD,
with units of pg/mL and mg/L for MCP-1 and hsCRP, respectively, or the median CAM score (normalized distribution value). For hsCRPmed, summary data are
presented as the percentage of subjects higher [1] or lower [0] than the median value for the indicated CAD class.
*P < 0.05.
Adj, adjusted model; CAD, coronary artery disease; CAM, cellular adhesion molecule; hsCRP, high-sensitivity C-reactive protein; hsCRPmed, median hsCRP;
MCP, monocyte chemoattractant protein; OR, odds ratio.observe the same association of rs394408 with either PF4
(Figure 4E) or PPBP (Figure 4F) expression as we did with
CXCL5 (Figure 4A).
Collectively, these data suggest PF4 and PPBP are cor-
egulated and under distinct transcriptional regulation
compared with CXCL5 in PMBCs in our cohort. More
important, we extended the rs394408-CXCL5 eQTL to the
protein level by measuring the genetic association of
rs394408 with circulating levels of CXCL5 (Figure 4G),
demonstrating that this eQTL extends to similar changes in
the circulating amount of CXCL5 peptide.
Humans have two homologs of the mouse CXCL5 gene,
CXCL5 and CXLC6. We examined the correlations between
CXCL5 levels in plasma and CXCL5 and CXCL6 expres-
sion in PMBCs. As expected, we identified a positive
correlation between the circulating levels and expression of
CXCL5 (r Z 0.4842, P Z 0.0042); however, there was no
correlation between CXCL6 and CXCL5 expression
(r Z 0.1134, P Z 0.1855) or between CXCL6 expressionand circulating CXCL5 levels (rZ 0.0567, PZ 0.5089), as
calculated by Pearson correlation analysis.
CXCL6 associated with diabetes in other clinical
cohorts.57 We also observed an association with CXCL6
expression in PMBCs with diabetes [b Z 0.38 (no CAD),
P Z 0.0312), but not with CAD class [b Z 0.06138 (no
CAD), P Z 0.4795], as calculated by t-test. A report on a
Han Chinese cohort in 201511 reported that CAD subjects
(n Z 77) had higher plasma levels of CXCL5 compared
with control participants (n Z 64), in stark contrast with our
observations (Figure 1B). However, diabetes, hypertension,
and smoking were all more prevalent in their CAD versus
control participants, and circulating CXCL5 appears to be
modified by diabetes in Chinese populations.12,58 These
additional inflammatory phenotypes were not distinguishing
factors in our data set (Table 1) nor did they have any
predictive power in our regression models (Supplemental








Figure 4 Genetic association with CXCL5
expression and circulating CXCL5 levels. A and B:
Expression quantitative trait loci (eQTL) analysis
of the expression regulatory single-nucleotide
polymorphism (eSNP) rs394408 with the number
of subjects, genotype, and CXCL5 expression levels
from either the Supporting a Multidisciplinary
Approach to Researching Atherosclerosis
(SAMARA) cohort (A) or dbGaP phs000424.v6.p1
(B), represented by box plots (5% to 95% CI) with
outliers identified (open circles). The P value and
b coefficient of the linear regression are noted. C:
The genetic locus of rs394408 on chromosome 4
with the physical position (in million bp; top) and
known genes; several eQTLs (green vertical lines;
middle) for CXCL5 identified in monocytes in the
region containing rs394408 (dark green line) and
further represented in the corresponding dot
plot of the log10 of the false-discovery rate
(q; bottom) were measured in a cohort of 1490
participants.53 D: Pairwise association analysis of
the indicated variables summarized by the
regression line and means (95% CIs). The corre-
lation coefficient for each association is indicated
and colored to reflect the P value. EeG: eQTL
analysis of the eSNP rs394408 with the genotype
and either PF4 (E) or PPBP (F) expression levels or
QTL analysis of rs394408 and plasma levels of
SAMARA subjects represented by box plots (5% to
95% CI) with outliers identified (open circles; G).
The P value and b coefficient of the linear
regression are noted. PF4, platelet factor 4; PPBP,
pro-platelet basic protein.CXCL5 Polymorphisms Associated with CAD in a Larger 
Cohort
Given the link between rs394408 and circulating levels of 
CXCL5 (Figure 4G), we used a dominant model with the 
minor allele that corresponded to increased CXCL5 levels. 
We found that the protective T allele associated with less 
severe CAD (Figure 5A), with an OR of 0.40 (95% CI, 
0.17e0.93) using a nominal CAD classification (Table 4), 
similar to the inverse relationship between circulating 
CXCL5 and disease severity (Table 2).
To test whether our CAD association findings could be 
replicated in other data sets, we used the genetic data from 
phase 1 of the SAMARA study (n Z 116; median 
age, 47 years; interquartile range, 43e49 years of age)17 and 
observed the same protective trend (Figure 5A) and eQTL 
(Figure 5B), finding the minor allele more prevalent in 
subjects without obstructive CAD (Table 4), with an OR of 
0.48 (95% CI, 0.22e1.05). We leveraged the data from 
phase 1 participants to allow us to more than double our 
study size (n Z 222), with which we calculated the OR of 
the minor allele and no obstructive CAD as 0.43 (95% CI, 
0.24e0.77). This larger cohort allowed us to examine all 
three genotypes of rs394408, and we found a dose-
dependent association of the minor allele with less severe 
CAD (Figure 5C), as expected given the presence of thelinear eQTL (Figure 5D). Consistent with our hypothesis,
we found that decreased CXCL5 expression associated with
obstructive CAD from phase 1, phase 2, and the combined
cohort via t-test (Figure 5E) and across all stages of CAD
via logistic regression in the combined cohort (Figure 5F).
These data suggest CXCL5 may modify disease risk in
younger populations as well.
Identifying Molecular Phenotypes of CXCL5-Related CAD in a
Geriatric Cohort
To identify molecular phenotypes associated with both
circulating CXCL5 and CAD severity, we analyzed
whether gene expression changes correlated with CAD
severity (ordinal), resulting in 681 probes (618 unique
genes; absolute rs  0.25, corresponding to P  0.0026;
false-discovery rate, <7%). We next compared the
SAMARA CAD expression signature with independent
analyses of case-control studies performed in younger
populations (all mean ages, <65 years).24 We compared
our list of 618 unique genes with the 655 genes that
significantly associated with CAD in analyses from both
the CATHGEN10 and Personalized Risk Evaluation and
Diagnosis in the Coronary Tree25 studies and identified
43 genes that overlapped (Table 5 and Supplemental























Figure 5 CXCL5 genetic association with coronary artery disease (CAD) in
additional cohorts. A and C: Contingency plot and P values of CAD status and
the minor allele of rs394408 in phase 1 (S1) or phase 2 (S2) of Supporting a
Multidisciplinary Approach to Researching Atherosclerosis (SAMARA; A) or in
the combined SAMARA cohort (C). B and D: Expression quantitative trait loci
analysis of the single-nucleotide polymorphism rs394408 with the number of
subjects, genotype, and relative CXCL5 expression levels from either phase 1
of SAMARA (B) or the combined SAMARA cohort (D), represented by box
plots (5% to 95% CI) with outliers identified (open circles). The P value and
b coefficient of the linear regression are noted. E and F: Plasma levels of
CXCL5 represented by dot plot and summarized by the means and 95% CIs of
the log values (pg/mL). E: Phase 1 (left), phase 2 (middle), or combined
(right) SAMARA subjects were stratified by obstructive CAD status. F: Plasma
levels of CXCL5 in subjects with increasing CAD severity, with the corre-
sponding P value of the logistic regression analysis. DeF: The combined data
sets used the z-scores of relative CXCL5 expression within each cohort.
*P < 0.05, **P < 0.01 versus the decreased CXCL5 levels in subjects with
obstructive CAD (t-test).




n P value OR (95% CI)
Reciprocal
OR
SAMARA 1 116 0.0612 0.48 (0.22e1.05) 2.15
SAMARA 2 106 0.0330 0.40 (0.17e0.93) 2.51
SAMARA 1
and 2
222 0.0037 0.43 (0.24e0.77) 2.31
We measured the association between the minor allele of rs394408
(TT þ TC 4 CC ) and CAD status (nominal) using contingency analysis. The
P value of the effect likelihood test for each analysis and the OR (95% CI)
are provided as well as the reciprocal OR.
CAD, coronary artery disease; OR, odds ratio; SAMARA, Supporting a
Multidisciplinary Approach to Researching Atherosclerosis.overlapping genes expected by chance (Table 5). These
results indicate that, although some of the gene expres-
sion changes in our cohort of older individuals are similar
to previously validated signatures in younger populations,there are likely age-dependent CAD changes in gene
expression reflected in our cohort.
We then overlapped our CXCL5 and CAD gene lists
and identified 253 probes associated with both circulating
CXCL5 levels and CAD severity (Figure 6A). The size of
the probe overlap was more than six times larger than
expected by chance (expected by chance, 36 probes)
(Table 5), suggesting that the inverse correlation between
circulating CXCL5 levels and CAD severity extends to
the molecular phenotype of gene expression. This is
evident in the inverse correlations between the 253
overlapping probes (Figure 6B). For a broader overview
of functional themes represented in the overlapping gene
set, we performed overrepresentation analysis of immu-
nological signatures and curated gene sets60 within these
two clusters of genes (Figure 6B). Genes negatively
associated with plasma levels of CXCL5 (and positively
associated with CAD severity) were enriched for genes
previously shown to be increased in systolic heart
failure61 and aging62 (Supplemental Table S7). They
were also enriched for several sets of genes that are
down-regulated in B cells compared with monocytes,
dendritic cells, or neutrophils,63 suggesting changes in
immune cell gene expression. Likewise, healthy immune
response gene expression changes64,65 and T-cell sig-
natures66e68 were associated with increased CXCL5
levels (Supplemental Table S7).
We used eQTL analyses and gene expression levels as
intermediate molecular phenotypes to understand how
variation in cis regulatory regions contribute to disease-
associated gene expression. Therefore, we further filtered
the CXCL5-CAD genes that also had an eSNP within 1E6
bases of the gene probe. We used associative statistical
methods using a linear model and identified 30 SNP-gene
associations (cis eQTLs) (Table 6) at 18 loci (Figure 6C).
One gene, LPCAT2, accounted for six eQTLs from two high
linkage disequilibrium clusters of eSNPs (Figure 7, A and
B). LPCAT2 expression was positively associated with
CAD severity when CAD classified as either an ordinal or a
nominal variable (Figure 7C). We validated these LPCAT2
Table 5 Over-Representation Analysis of Gene Lists
Comparison Set 1 Set 2 Overlap Total Representation factor P value
SAMARA vs CATHGEN/PREDICT* 618 655 43 29,281y 3.1 6.70  1011
CXCL5 vs CADz 1041 681 253 18,425x 6.6 6.01  10145
Two sets of genes and their overlap were compared, and the representation factor and probability of finding an overlap of genes were calculated. The
representation factor is the number of overlapping genes/the expected number of overlapping genes drawn from two independent groups. A representation
factor >1 indicates more overlap than expected of two independent groups, a representation factor <1 indicates less overlap than expected, and a repre-
sentation factor of 1 indicates two groups by the number of genes expected for independent groups of genes. The probability (P) of finding more than the
number of identified overlapping genes was calculated using the hypergeometric probability formula.
*Indicates gene-level comparison (unique genes only).
yIndicates the number of unique genes (GenBank accessions) represented on the Agilent arrays used in the SAMARA, CATHGEN, and PREDICT studies.
zIndicates probe-level comparison.
xIndicates the number of probes that passed quality control in the SAMARA microarray data set used to identify CXCL5- and CAD-associated gene expression.
CAD, coronary artery disease; CATHGEN, CATHeterization GENetics; PREDICT, Personalized Risk Evaluation and Diagnosis in the Coronary Tree; SAMARA,
Supporting A Multidisciplinary Approach to Researching Atherosclerosis.eQTLs in the Kirsten data set on circulating monocytes from
>2000 individuals56 and found a similar pattern of lower
false-discovery rate in the linkage disequilibrium cluster ii




strong link between genetic variance and LPCAT2 expres-
sion (Supplemental Table S5).
LPCAT2 encodes an enzyme that synthesizes glycer-
ophospholipid precursors used in membrane biogenesis andHeart Failure
Aging
Figure 6 Expression quantitative trait loci
(eQTL) analysis associated with circulating CXCL5
levels and coronary artery disease (CAD) severity.
A: Venn diagram of gene expression that corre-
lated with either circulating CXCL5 levels (red),
CAD severity (green), or both (yellow) in the
Supporting a Multidisciplinary Approach to
Researching Atherosclerosis (SAMARA) cohort. B:
The overlapping 253 gene probes are represented
by a scatterplot of the Spearman correlation co-
efficients (rs) of each probe to circulating CXCL5
levels (y axis) versus CAD severity (x axis). The two
clusters of genes (dashed circles) were enriched
for distinct gene sets, as indicated (Supplemental
Table S4 provides a complete list). C: The heat
map represents the relative gene expression of 18
genes with identified eQTLs in the SAMARA cohort.
Each column represents one subject; the first and
second rows display the CAD score and CXCL5 rank,
respectively, followed by the individual gene
expression profile.
Table 6 Local Cis eQTL Identified in CAD Genes
rs Identification Gene symbol Gene description P value FDR, % b Value
rs12708952 LPCAT2 Lysophosphatidylcholine acyltransferase 2 3  107 0.1 0.52
rs4402561 LPCAT2 Lysophosphatidylcholine acyltransferase 2 4  107 0.1 0.49
rs1891241 LGALS8 Lectin, galactoside-binding, soluble, 8 2  106 0.4 0.33
rs1796415 RNF10 Ring finger protein 10 4  106 0.8 0.60
rs10158939 RP11-553N16.1* Known processed pseudogene 5  106 0.9 0.24
rs11254468 VIM Vimentin 7  106 1.3 0.43
rs6599244 RPL18AP7* Ribosomal protein L18a pseudogene 7 1  105 1.9 0.44
rs9511357 ZMYM5 Zinc finger, MYM-type 5 1  105 2.2 0.18
rs831757 ARL8A ADP-ribosylation factor-like 8A 2  105 2.5 0.23
rs2799428 LGALS8 Lectin, galactoside-binding, soluble, 8 2  105 2.8 0.29
rs244836 COTL1 Coactosin-like F-actin binding protein 1 2  105 2.9 0.23
rs1583585 LPCAT2 Lysophosphatidylcholine acyltransferase 2 2  105 3.2 0.41
rs1963773 RNF10 Ring finger protein 10 2  105 3.4 0.45
rs41416850 RNF10 Ring finger protein 10 2  105 3.4 0.63
rs2737706 LGALS8 Lectin, galactoside-binding, soluble, 8 3  105 3.7 0.30
rs1583587 LPCAT2 Lysophosphatidylcholine acyltransferase 2 3  105 3.9 0.42
rs3779647 GSR Glutathione reductase 3  105 4.0 0.19
rs913863 RRAGC Ras-related GTP binding C 4  105 4.8 0.10
rs11646643 LPCAT2 Lysophosphatidylcholine acyltransferase 2 5  1005 6.0 0.41
rs9989481 UBALD2 UBA-like domain containing 2 6  105 6.3 0.24
rs11206237 TALDO1 Transaldolase 1 6  105 6.8 0.44
rs913863 RRAGC Ras-related GTP binding C 7  105 7.3 0.10
rs1477017 LPCAT2 Lysophosphatidylcholine acyltransferase 2 7  105 7.6 0.40
rs1799917 LPCAT2 Lysophosphatidylcholine acyltransferase 2 7  105 7.6 0.41
rs2715143 GRB10 Growth factor receptor-bound protein 10 7  105 7.6 0.84
rs9553323 ZMYM5 Zinc finger, MYM-type 5 7  105 7.7 0.17
rs4415303 GYG1P1* Glycogenin 1 pseudogene 1 8  105 7.8 0.49
rs1611699 HLA-K* Major histocompatibility complex, class I, K 9  105 8.5 0.18
rs3013777 YIPF1 Yip1 domain family, member 1 1  104 9.5 0.21
rs11185517 NCBP2-AS2 NCBP2 antisense RNA 2 (head to head) 1  104 9.7 0.16
The single-nucleotide polymorphism identifier (rs identification), official gene symbol and description, and the P values, FDRs, and b values from the linear
model are provided.
*Gene symbols and descriptions updated in BioMart that were not initially annotated.
CAD, coronary artery disease; eQTL, expression quantitative trait loci; FDR, false-discovery rate; HLA, human leukocyte antigen; MYM, myeloproliferative and
mental retardation motif; NCBP, Nuclear Cap Binding Protein Subunit; UBA, ubiquitin-associated domain; Yip, Ypt-interacting proteins.the inflammatory lipid platelet-activating factor. Because
LPCAT2 is expressed in circulating blood cells, we
extended our QTL and correlation analyses to platelet
counts and PF4 expression levels to determine whether
variation at rs12708952 associates with altered platelet
levels or platelet activation. The correlation between
LPCAT2 and either platelet counts or PF4 expression was
weak and opposed (Supplemental Figure S2). Furthermore,
there was no association between variation at rs12708952
and either platelet counts or PF4 expression (Figure 7D),
suggesting that the repercussions of LPCAT2 expression do
not extend to these measures of platelet function and that
perhaps other pathways or signaling affected by LPCAT2
expression may be important to the phenotypes observed in
our study. In addition to being expressed in circulating
blood cells, LPCAT2 is expressed throughout the body.
Given the complex nature of CVD, we looked for tissue
specific for the LPCAT2 eQTLs from cluster ii from dbGAP.
Interestingly, we found the presence of tissue-specificeQTLs, including adipose tissue and various blood ves-
sels, suggesting that LPCAT2 biology in these tissues, in
addition to circulating blood cells, may be important in
human CAD (Figure 7A).Discussion
As the percentage of our population that is 65 years and
older increases annually, it is important to understand the
genetic and molecular underpinnings of CAD in geriatric
patients. To assess the relationship between CXCL5,
the severity of CAD, and the corresponding molecular
phenotypes, we characterized the circulating levels of
CXCL5 and other proinflammatory markers, gene
expression patterns, and genetic variation in patients 65
years and older who were undergoing cardiac catheteri-
zation (Table 1). Interestingly, we identified a negative





×10-7 ×10-5severity (Table 2). Similar to a prior report of an inverse
relationship between CXCL5 activity and atherosclerosis
in a mouse model,13 our clinical data are consistent with a
protective role of CXCL5 in CAD (Figure 1). To ensure
our observation was not confounded by other known fac-
tors that could influence CXCL5 levels, we extensively
examined several covariates, such as sex (Figures 1B and
2B), circulating lipid levels (Figure 2A), inflammatory
biomarkers (Table 3 and Supplemental Tables S2 and S3),
prior MI (Figure 3), and statin use (Figure 2, BeD).
Interestingly, there was no association between prior statin
use and CXCL5 levels, but by using various stratifications,
we identified a decrease in CXCL5 levels in female statin
users with obstructive CAD (Figure 2B). The high-
intensity statin, rosuvastatin, had a differential effect on
CXCL5 levels (Figure 2C), suggesting that statin intensity
and sex-specific effects of statins on CXCL5 biology
should be considered in future clinical studies. Although
white blood cell counts did not correlate with plasma
levels of CXCL5, we identified a positive correlation be-
tween platelet counts and CXCL5 (Figure 2A). These data
suggest that platelets could be a physiologically important
source of CXCL5 in the context of CAD. Previous studies
in mice demonstrated that aortic endothelial cells are an
important source of CXCL5 in proatherogenic condi-
tions,13 highlighting the need to better understand the
production and turnover of CXCL5 in physiological and
pathophysiological conditions.
Genomic analyses of our cohort revealed a genetic
contribution to CXCL5 expression (Figures 4A and 5, B
and D) that ultimately extended to both circulating plasma
CXCL5 levels (Figure 4G) and CAD severity (Figure 5,
A, C, E, and F). Furthermore, the eSNP rs394408 corre-
sponds specifically with CXCL5 expression levels and not
PF4 or PPBP, which are in close proximity (Figure 4C).
Furthermore, gene expression changes that were commonFigure 7 Expression quantitative trait loci (eQTL) analysis associated
with circulating CXCL5 levels and coronary artery disease (CAD) severity. A:
Linkage disequilibrium analysis (top) of six expression regulatory single-
nucleotide polymorphisms (eSNPs) at the locus of LPCAT2 on chromosome 16
from black and white American 1000 genomes population data (represented
in million bp; middle) identified two clusters of correlated SNPs (i and ii).
Tissues where four of the LPCAT2 eQTLs were also present are indicated
(bottom), with the effect size and significance level indicated by color in-
tensity and size, respectively, from dbGaP phs000424.v6.p1. B: eQTL analysis
of the eSNP rs12708952 (left panel) and rs11646643 (right panel) with the
number of subjects per genotype from the Supporting a Multidisciplinary
Approach to Researching Atherosclerosis (SAMARA) cohort represented by
box plots (5% to 95% CI) with outliers identified (open circles). The P value
and b coefficient of the linear regression are noted. C: LPCAT2 expression
versus CAD severity in the SAMARA cohort is represented by dot plot, sum-
marized by the means and 95% CIs, classified as a nominal (left panel) or an
ordinal (right panel) variable, with the corresponding P value from either a
t-test or logistic regression, respectively. D: QTL analysis of rs12708952 and
platelet counts (left panel) or PF4 expression (right panel), represented by
box plots (5% to 95% CI) with outliers identified (open circles). The P value
and b coefficient of the linear regression are noted.
to both plasma CXCL5 levels and CAD severity
(Figure 6A) also had an inverse relationship, suggesting
that genomic analyses provide a unique molecular insight
into the relationship between CXCL5 and CAD severity
(Figure 6B). This approach revealed the dysregulation of
LPCAT2 (Figures 6C and 7, B and C), an enzyme
involved in both glycerophospholipid precursor synthesis
to help maintain inflammatory cell membrane integrity
and synthesis of platelet-activating factor. This factor is a
potent phospholipid activator that affects vascular
permeability and chemotaxis of leukocytes, platelet
aggregation and degranulation, and inflammation; it also
causes a negative inotropic effect.69 In addition to the
presence of LPACT2 eQTLs in PBMCs (Figure 7B) and
isolated monocytes (Supplemental Table S5), multitissue
analysis (Figure 7A) identified these same eQTLs in
vascular tissues, such as the aorta and tibial arteries, and
adipose tissue. The presence of tissue-specific eQTLs
suggests that LPCAT2 expression in these tissues may
play a role in the disease susceptibility identified in our
study (Figure 7C).
How is CXCL5 regulated during the development of
CAD? In ApoE/ mice, plasma CXCL5 levels increased
threefold after 6 weeks of a Western diet and remained
elevated throughout atherogenesis.13 In a Chinese Han
cohort, higher plasma CXCL5 levels were found in
CAD patients compared with subjects without CAD.11
However, CAD severity was not considered, and other
chronic inflammatory conditions, including diabetes
and hypertension, were more commonly comorbid with
CAD in these subjects. These reports, combined with
the data presented herein, suggest that CXCL5 increases
with the onset of atherosclerosis and maintaining (or
further increasing) CXCL5 levels may protect against
obstructive CAD. This provides a clinical extension
of mouse studies in which CXCL5 was directly manip-
ulated to demonstrate the atheroprotective effect of this
chemokine.13
Other studies demonstrated that markers, such as
MCP-1, selectins, and CAMs, positively associate with
CAD41,70; however, our study did not reveal any associa-
tions between CAD severity and these inflammatory
markers. The only other marker in our analyses that posi-
tively associated with CAD was hsCRP (Table 3).
Numerous studies reported positive associations of hsCRP
with CAD,44,45 although studies using a mixed population
of older and younger patients reported no association be-
tween hsCRP and CAD.71e73 Further studies that evaluate
younger and geriatric populations separately, and analysis
of longitudinal studies over age, are necessary to identify
the distinct pathophysiological processes in CAD that are
likely modified by aging. For example, we observed a
similar, but weaker, genetic association between CXCL5
and CAD in a younger cohort (Figure 5, A and B), sug-
gesting that CXCL5 may play a role, even in younger
patients with CAD.It is important to identify the limitations of our study.
First, our patient population consists of subjects referred
to the cardiac catheterization laboratory for clinically
indicated coronary angiography; therefore, we lack a true
age-matched, healthy control group, a known challenge in
the genetic characterization of CAD.74 However, our
cohort did include patients with little or no angiograph-
ically detectable CAD. Second, our sample size for
genomic analyses (n Z 106) prevented us from per-
forming additional analyses, such as genome-wide asso-
ciations or trans-eQTL identification. Therefore, we
leveraged our data by combining genetic and transcrip-
tional data sets, and we used public data sets to serve as
validation cohorts for our genomic findings. In addition,
we validated our primary findings from phase 1 of
SAMARA to increase the power of our contingency
analysis looking at disease risk and the protective allele at
rs394408. Although our study demonstrates that CXCL5
levels are diminished with increasing CAD severity,
future longitudinal studies tracking CXCL5 expression
over age are necessary to elucidate the role of CXCL5 in
disease initiation and progression. In addition, cell and
animal studies can be used to elucidate the role of the
biological interaction of CXCL5 and LPCAT2 in both the
pathology of atherosclerosis and the design of new ther-
apeutic interventions to modify disease risk.Acknowledgments
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